• Displaying 1 - 10 of 11
  • First
  • «
  • 1
  • 2
  • 3
  • 4
  • 5
  • »
  • Last
P01 - Decisions Surrounding Conservative Care Are not Absolute
Candice Halinski, MBA, MHCDS, MSN, NP-C, AMB-BC, Director, Service Line Clinical, North Shore LIJ
Tags: conservative care treatment options medical management without dialysis

Updated: 04/26/21

Updated: 04/26/21
Reader will identify conversion rate and characteristics of patients who reversed their decision to pursue conservative care.
P02 - Implementation of Continuous Renal Replacement Therapty (CRRT) with COVID-19, Prismaflex to Prismax, and Citrate Anticoagulation
Isagani I. Marquez, MSN, RN, QUIA    |     Charilyn Fox, MHA, BSN, RNc    |     John Gabriel, BSN, RN
Tags: continous renal replacement

Updated: 04/26/21
Implementation of Continuous Renal Replacement Therapy, monitoring the treatment and training and initiating Prismaflex/Prismax and ACDA anticoagulation.
P03 - Exercise in Outreach
Carolyn A. Boone, MSN, RN, CCTC
Tags: referral transplant

Updated: 04/26/21

Updated: 04/26/21
Discuss ways to increase referral to transpalnt center
P04 - Enhancing Patients Experience: A Support Group for Home Dialysis Patients
Chechemma George, BSN, RN, CNN    |     James J. Peters, BSN, RN, CNN
Tags: quality of life support group

Updated: 04/26/21
Empower Home Dialysis patients through support group
P05 - The Benefits on Quality of Life for Children with a Transplant Attending a Specialty Camp
Cindy A. Richards, BSN, RN, CNN, CCTC, Pediatric Kidney Transplant Coordinator    |     Patricia Patterson, RN, CNN, Patient Safety and Risk Coordinator, St. Vincent's Hospital
Tags: transplantation camp children chronic illness

Updated: 04/26/21

Updated: 04/26/21

Describe one benefit to their quality of life (QoL) to a child with a kidney or other solid organ transplant from attending a specialty camp.

P06 - COVID-19 in the Inpatient Dialysis Setting
Leslie Senyitko, MSN, RN, CNN, NE-BC
Tags: COVID-19 inpatient dialysis setting

Updated: 04/26/21

Updated: 04/26/21
TBD
P07 - Addressing the Issue: Sexual Health of Patients with Chronic Kidney Disease
Anita Settles-Seymour, MSN, RN    |     Melody N. Waller, PhD, RN    |     Jami S. Brown, DHEd, MSN, RN, CNN, FANNA, Associate Professor, The University of Tennessee Health Science Center
Tags: sexual dysfunction Sexual health barriers sexual health progress of CKD Sexual health strategies

Updated: 04/26/21

Updated: 04/26/21
Sexual dysfunction is a common, multifactorial problem affected by various physiological and psychological factors associated with the progression of chronic kidney disease (CKD). The interprofessional team needs to be knowledgeable of the causes and complications of CKD and identify barriers and strategies in addressing the sexual health of patients with CKD.
P09 - Improvements in Itch-Related Quality of Life With Difelikefalin for Moderate-to-Severe Chronic Kidney Disease–Associated Pruritus: Pooled Analysis of KALM-1 and KALM-2 Phase 3 Studies in Hemodialysis Patients
Molly L. Cahill, MSN, APRN, BC, NP-C, CNN, FNKF, Nurse Practitioner, KC Kidney Consultants    |     Steven Fishbane, MD, Chief, Division of Nephrology, Northwell Health    |     Thomas Wooldridge, MD    |     Warren Wen, PhD    |     Catherine Munera, PhD    |     Frederique Menzaghi, PhD
Tags: chronic kidney disease quality of life pruritus difelikefalin

Updated: 04/26/21

Updated: 04/26/21
The participant will be able to describe efficacy of difelikefalin for improving itch-related quality of life in patients with moderate-to-severe chronic kidney disease–associated pruritus
P10 - Prevalence of Intradialytic Hypotension (IDH) across Crit-Line Profiles in the Acute Setting: A Retrospective Data Analysis
Jacqueline Chandler, RN, BA, CNN    |     Suman Khanna, BSN    |     Abeera Mansur, MD

Updated: 04/26/21

Updated: 04/26/21
P11 - ILLUMINATE-B, a Phase 3 open-label study to evaluate lumasiran, an RNAi therapeutic, in young children with primary hyperoxaluria type 1 (PH1)
Debbie Barrera, BSN    |     Georges Deschenes, MD    |     Pierre Cochat, MD    |     Daniella Magen, MD    |     William VantHoff, MD    |     Mini Michael, MD    |     David Sas, MD    |     Gesa Schalk, MD    |     Hadas Sasha-Lavsky, MD    |     Wesley Hayes, MD    |     Kyoungwha Bae, PhD    |     Ali Seddighzadeh, MD    |     Pushkal Garg, MD    |     Akshay Vaishnaw, MD    |     Tracy McGregor, MD    |     Kenji Fujita, MD    |     Yaacov Frishberg, MD
Tags: primary hyperoxaluria type 1 PH1 lumasiran oxalate

Updated: 04/26/21

Updated: 04/26/21
Participants will be able to evaluate the impact of lumasiran, a RNAi therapuetic in young children with primary hyperoxaluria type 1 (PH1)- a rare genetic kidney disorder
  • Displaying 1 - 10 of 11
  • First
  • «
  • 1
  • 2
  • 3
  • 4
  • 5
  • »
  • Last